Literature DB >> 12033958

Excisional biopsy should be performed if lobular carcinoma in situ is seen on needle core biopsy.

Sandra J Shin1, Paul Peter Rosen.   

Abstract

CONTEXT: Percutaneous image-guided core biopsy is increasingly becoming the method of choice to evaluate impalpable breast lesions presenting with mammographically detected calcifications or as a mammographically detected mass. Infrequently, a diagnosis of a primary lobular lesion is rendered by needle core biopsy. Although lobular carcinoma in situ (LCIS) and atypical lobular hyperplasia (ALH) are not themselves detectable by mammography, they can be associated with calcifications. The management of patients with a primary diagnosis of LCIS or ALH on needle core biopsy is uncertain. Recommendations include excisional biopsy, tamoxifen citrate therapy, mammographic surveillance, or a combination of these approaches.
OBJECTIVE: The purpose of this study was to report the histologic findings of excisional biopsies performed after ALH or LCIS was found in a needle core biopsy.
DESIGN: Hematoxylin-eosin-stained slides of 20 needle core biopsy specimens from patients with a primary diagnosis of LCIS or ALH were retrieved from the consultation and surgical pathology files of New York Presbyterian Hospital-Weill Medical College of Cornell University. Histologic diagnoses were confirmed in all cases.
RESULTS: Fourteen cases of primary LCIS and 6 cases of ALH found on needle core biopsy were identified. Subsequent excisional biopsy of the 14 LCIS cases revealed the following: LCIS, ductal carcinoma in situ, invasive carcinoma (1 patient; 7%); LCIS, infiltrating lobular carcinoma (1 patient; 7%); LCIS, ductal carcinoma in situ (1 patient; 7%); LCIS (8 patients; 57%); and ALH with or without atypical ductal hyperplasia (3 patients; 21%). Among the 6 patients with ALH on needle core biopsy, 1 had infiltrating lobular carcinoma and LCIS and 2 had LCIS in subsequent excision; other excisions for ALH were benign. Overall, 3 (21%) of 14 patients with a primary diagnosis of LCIS on needle core biopsy had a more significant lesion (ductal carcinoma in situ or invasive carcinoma) in a subsequent excisional biopsy.
CONCLUSIONS: Data obtained in this study and in previously published reports lead us to conclude that excisional biopsy may be indicated and should be considered when LCIS is found on needle core biopsy in order to more fully examine the biopsy site for coexistent, clinically inapparent intraductal or invasive carcinoma that may be present in about 25% of these patients. The small number of ALH cases studied produced inconclusive results. We recommend that excisional biopsy be considered if atypical ductal hyperplasia is present with ALH in a needle core biopsy or if the diagnosis of the biopsy specimen is discordant with the mammographic findings.

Entities:  

Mesh:

Year:  2002        PMID: 12033958     DOI: 10.5858/2002-126-0697-EBSBPI

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  16 in total

1.  Early Breast Cancer Precursor Lesions: Lessons Learned from Molecular and Clinical Studies.

Authors:  Hans-Peter Sinn; Zeinab Elsawaf; Birgit Helmchen; Sebastian Aulmann
Journal:  Breast Care (Basel)       Date:  2010-08-23       Impact factor: 2.860

2.  [Concepts and problems of lobular neoplasia].

Authors:  H P Sinn; B Helmchen; S Aulmann
Journal:  Pathologe       Date:  2006-09       Impact factor: 1.011

3.  AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2014.

Authors:  Cornelia Liedtke; Marc Thill; Volker Hanf; Florian Schütz
Journal:  Breast Care (Basel)       Date:  2014-07       Impact factor: 2.860

Review 4.  Upgrade rates of high-risk breast lesions diagnosed on core needle biopsy: a single-institution experience and literature review.

Authors:  Kelly L Mooney; Lawrence W Bassett; Sophia K Apple
Journal:  Mod Pathol       Date:  2016-08-19       Impact factor: 7.842

5.  UK national survey of management of breast lobular carcinoma in situ.

Authors:  R Chester; O Bokinni; I Ahmed; A Kasem
Journal:  Ann R Coll Surg Engl       Date:  2015-11       Impact factor: 1.891

Review 6.  Pathologic High-risk Lesions, Diagnosis and Management.

Authors:  Melissa Murray
Journal:  Clin Obstet Gynecol       Date:  2016-12       Impact factor: 2.190

Review 7.  Lobular Carcinoma In Situ.

Authors:  Hannah Y Wen; Edi Brogi
Journal:  Surg Pathol Clin       Date:  2017-12-08

8.  Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 020).

Authors:  Faina Nakhlis; Lauren Gilmore; Rebecca Gelman; Isabelle Bedrosian; Kandice Ludwig; E Shelley Hwang; Shawna Willey; Clifford Hudis; J Dirk Iglehart; Elizabeth Lawler; Nicole Y Ryabin; Mehra Golshan; Stuart J Schnitt; Tari A King
Journal:  Ann Surg Oncol       Date:  2015-11-05       Impact factor: 5.344

Review 9.  Non-operative breast pathology: lobular neoplasia.

Authors:  Jorge S Reis-Filho; Sarah E Pinder
Journal:  J Clin Pathol       Date:  2006-12-20       Impact factor: 3.411

10.  The Role of Proteomics in the Diagnosis and Treatment of Women's Cancers: Current Trends in Technology and Future Opportunities.

Authors:  Eun-Kyoung Yim Breuer; Mandi M Murph
Journal:  Int J Proteomics       Date:  2011-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.